Antidepressants: psychiatrists' opinions and clinical practice

被引:12
作者
Depont, F
Rambelomanana, S
Le Puil, S
Begaud, B
Verdoux, H
Moore, N
机构
[1] Univ Victor Segalen, Dept Pharmacol, F-33076 Bordeaux, France
[2] Univ Victor Segalen, Dept Adult Psychiat, Publ Hlth Res Inst, IFR99, F-33076 Bordeaux, France
关键词
antidepressive agents; depression; depressive disorder; drug; physician's practice patterns; prescriptions; treatment outcome;
D O I
10.1034/j.1600-0447.2003.00088.x
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: To describe and compare psychiatrists' opinion on antidepressant drugs and their prescriptions to depressed patients. Method: Between January and September 1999 a representative sample of French psychiatrists was asked their opinion of the 15 most prescribed antidepressants, and then to describe the treatments of the current depressive episode of four depressive patients each, their changes and the reason thereof. Results: A total of 232 psychiatrists and 935 patients participated. The best ranked antidepressants were clomipramine, paroxetine and amitriptyline for efficacy, tianeptine, paroxetine and citalopram for tolerability. In patients, the most often prescribed were paroxetine, fluoxetine and venlafaxine. Those least often stopped for intolerance were tianeptine (2.9%), citalopram (5.2%), venlafaxine (3.3%) and amitriptyline (5.7%) for lack of efficacy. There was no difference in stopping rates for inefficacy of tricyclics and serotonin-selective agents. Conclusion: The best predictors for the prescribed antidepressants were the psychiatrists' overall rankings and opinions of the tolerability of the drug.
引用
收藏
页码:24 / 31
页数:8
相关论文
共 33 条
  • [1] TREATMENT DISCONTINUATION WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS COMPARED WITH TRICYCLIC ANTIDEPRESSANTS - A METAANALYSIS
    ANDERSON, IM
    TOMENSON, BM
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1995, 310 (6992): : 1433 - 1438
  • [2] DISCONTINUATION OF ANTIHYPERLIPIDEMIC DRUGS - DO RATES REPORTED IN CLINICAL-TRIALS REFLECT RATES IN PRIMARY-CARE SETTINGS
    ANDRADE, SE
    WALKER, AM
    GOTTLIEB, LK
    HOLLENBERG, NK
    TESTA, MA
    SAPERIA, GM
    PLATT, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (17) : 1125 - 1131
  • [3] Anthony J C, 1991, Epidemiology, V2, P123
  • [4] Armstrong D, 1996, BRIT MED J, V312, P949
  • [5] Forty years of antidepressant drug trials
    Barbui, C
    Hotopf, M
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 2001, 104 (02) : 92 - 95
  • [6] Benson, 2000, Am J Ophthalmol, V130, P688, DOI 10.1016/S0002-9394(00)00754-6
  • [7] A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder
    Chouinard, G
    Saxena, B
    Bélanger, MC
    Ravindran, A
    Bakish, D
    Beauclair, L
    Morris, P
    Nair, NPV
    Manchanda, R
    Reesal, R
    Remick, R
    O'Neill, MC
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 1999, 54 (1-2) : 39 - 48
  • [8] PHYSICIANS BEHAVIOR AND THEIR INTERACTIONS WITH DRUG COMPANIES - A CONTROLLED-STUDY OF PHYSICIANS WHO REQUESTED ADDITIONS TO A HOSPITAL DRUG FORMULARY
    CHREN, MM
    LANDEFELD, CS
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (09): : 684 - 689
  • [9] Randomized, controlled trials, observational studies, and the hierarchy of research designs.
    Concato, J
    Shah, N
    Horwitz, RI
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (25) : 1887 - 1892
  • [10] IMPACT OF CLINICAL-TRIALS ON THE ADOPTION OF NEW DRUGS WITHIN A UNIVERSITY HOSPITAL
    DENIG, P
    HAAIJER-RUSKAMP, FM
    WESSELING, H
    VERSLUIS, A
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 41 (04) : 325 - 328